| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $6,964,448 ) |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 000 | 2 | NIH | 9/3/2025 | $677,620 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R33DA059033 | Implementing a patient navigation intervention across a health system to improve outcomes for patients with opioid use disorder | 000 | 2 | NIH | 7/31/2025 | $1,130,715 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 3 | NIH | 7/18/2025 | $1,129,361 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 2 | NIH | 7/30/2025 | $773,197 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 003 | 3 | NIH | 7/18/2025 | $917,615 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21DA062508 | Leveraging a time-limited opportunity to study the impact of an intervention for individuals bereaved by drug overdose | 000 | 1 | NIH | 1/30/2025 | $197,250 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Take-home expansion: Scope and impact study (THESIS) | 000 | 4 | NIH | 7/23/2025 | $633,988 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 003 | 4 | NIH | 8/1/2025 | $901,066 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 000 | 2 | NIH | 7/25/2025 | $280,478 |
| | 2025 | 2025 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UM1DA064499 | A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail | 000 | 1 | NIH | 9/5/2025 | $1,393,922 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 2 | NIH | 4/10/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 004 | 2 | NIH | 7/25/2025 | $534,010 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 002 | 2 | NIH | 6/27/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 001 | 2 | NIH | 6/22/2025 | -$534,010 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 000 | 2 | NIH | 3/21/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 002 | 3 | NIH | 6/27/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 001 | 3 | NIH | 6/22/2025 | -$707,335 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 000 | 3 | NIH | 3/21/2025 | $0 |
| | 2025 | 2024 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 5 | NIH | 1/29/2025 | $0 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 002 | 5 | NIH | 3/6/2025 | $0 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 5 | NIH | 3/5/2025 | $0 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 003 | 5 | NIH | 3/18/2025 | $0 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 10/1/2024 | -$245,497 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 001 | 5 | NIH | 4/7/2025 | $0 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 002 | 5 | NIH | 4/17/2025 | $0 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 10/1/2024 | -$117,932 |
| | 2025 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA040636 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 6/22/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $6,425,291 ) (Continued on the next page) |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R18HS029783 | Leveraging social determinants via artificial intelligence and peer coaching to address racial disparities in primary care among people who use opioids | 003 | 3 | AHRQ | 8/23/2024 | $564,435 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 5 | NIH | 1/8/2024 | $503,863 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 001 | 5 | NIH | 4/25/2024 | $55,985 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 001 | 2 | NIH | 5/17/2024 | $555,180 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 000 | 2 | NIH | 6/17/2024 | $896,441 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 000 | 1 | NIH | 9/6/2024 | $157,603 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Take-home expansion: Scope and impact study (THESIS) | 000 | 3 | NIH | 6/17/2024 | $682,722 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder | 000 | 3 | NIH | 6/21/2024 | $912,089 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 000 | 3 | NIH | 7/5/2024 | $236,463 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 001 | 1 | NIH | 8/21/2024 | $225,981 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 000 | 1 | NIH | 6/27/2024 | $225,981 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 002 | 1 | NIH | 8/27/2024 | $0 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 001 | 1 | NIH | 8/21/2024 | -$225,981 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 001 | 2 | NIH | 5/24/2024 | $1,086,043 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R18HS029783 | Leveraging social determinants via artificial intelligence and peer coaching to address racial disparities in primary care among people who use opioids | 001 | 2 | AHRQ | 5/10/2024 | $548,486 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 1 | NIH | 10/23/2023 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA059033 | Implementing a patient navigation intervention across a health system to address treatment entry inequities | 000 | 1 | NIH | 12/8/2023 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 5/9/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 5 | NIH | 9/19/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 4/4/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 1 | NIH | 2/2/2024 | $0 |
|
